Skip to main navigation
Overview
Newsroom
News Releases
Corporate Statements
Multimedia Resources
Events & Presentations
Events
Presentations
Financials
SEC Filings
Annual Reports
Stock Information
Stock Quote & Chart
Analyst Coverage
Investor FAQs
Corporate Governance
Governance Documents
Committee Composition
Leadership
Code of Business Conduct
Corporate Responsibility
Contact the Board
Top bar
Biogen.com
Information Request
Sign up for Alerts
Search
Search
Search
News
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
News
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
SEC Filings
Form 8-K
SEC Filings
Form 10-Q
News
Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World
News
Biogen Announces Departure of Tony Kingsley
News
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS
News
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
SEC Filings
Form 4
News
Biogen Announces Webcast of Investor R&D Day
Pagination
Previous page
‹‹
Page 2
Next page
››
Filter by gallery
No facets
Your selection
Clear all
2015
Remove
Filter by category
Filter by category
Filter by category
Filter by category
Filter by type
Filter by tags
Filter by form group
Filter by content year
(-)
2015
(173)
Filter by content type
SEC filing
(109)
News
(62)
Asset
(2)
Tools
Print Page
Stockholder Communications
E-mail Alerts
FAQs
Facebook
Twitter
LinkedIn
Google+
